Teva Pharmaceutical Industries Limited Sponsored ADR Stock

$13.27

2.82%

NYSE, Apr 21, 09:16 pm CET

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$13.65

+3.38 32.91% 5Y

NYSE, Closing price Thu, Apr 17 2025

+0.22 1.64%

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$15.64b
Enterprise Value	$30.85b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	15.12
EV/Sales (TTM) EV/Sales	1.87
P/S ratio (TTM) P/S ratio	0.95
P/B ratio (TTM) P/B ratio	2.88
Revenue growth (TTM) Revenue growth	4.34%
Revenue (TTM) Revenue	$16.53b
EBIT (operating result TTM) EBIT	$3.35b
Free Cash Flow (TTM) Free Cash Flow	$2.04b
Cash position	$3.30b
EPS (TTM) EPS	$-1.45
P/E forward	6.01
P/S forward	0.91
EV/Sales forward	1.79
Short interest	2.84%

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Get Started for Free Today

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

8x Buy

73%

2x Hold

18%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Buy

73%

Hold

18%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	16,531 16,531	4% 4% 100%
- Direct Costs	8,480 8,480	3% 3% 51%
Gross Profit	8,051 8,051	5% 5% 49%
- Selling and Administrative Expenses	2,642 2,642	13% 13% 16%
- Research and Development Expense	999 999	5% 5% 6%
EBITDA	4,410 4,410	1% 1% 27%
- Depreciation and Amortization	1,059 1,059	8% 8% 6%
EBIT (Operating Income) EBIT	3,351 3,351	5% 5% 20%
Net Profit	-1,638 -1,638	211% 211% -10%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Neutral

The Motley Fool

●

about 12 hours ago

Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now

When examined over long stretches, stocks stand atop the pedestal in terms of annualized return, relative to all other asset classes. But this doesn't mean the Dow Jones Industrial Average (^DJI -1.33%), S&P 500 (^GSPC 0.13%), and Nasdaq Composite (^IXIC -0.13%) move from Point A to B in a straight line.

Positive

24/7 Wall Street

●

5 days ago

Billionaire Sold Broadcom And Bought This Stock That Could Soar 121%

TEVA has 121% upside from its share price today. Retiring early is possible, and may be easier than you think.

Positive

The Motley Fool

●

9 days ago

5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility

For more than a century, the stock market has been the premier wealth creator for investors. But this doesn't mean stocks move higher in a straight line.

More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office	Israel
CEO	Richard Francis
Employees	36,167
Founded	1901
Website	www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now